rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ARGX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Cradle's Antibody Discovery Platform for Autoimmune Diseases Supports Scientific Mission of argenx

      Cradle, today announced that argenx is expanding use of Cradle's end-to-end AI-driven protein engineering platform to more scientists and antibody discovery programs following successful results from its initial work.

      Nov 17Yahoo FinanceARGX
      argenx (ENXTBR:ARGX) Stock May Look Fully Priced Despite Its $1.15B Deal
      Nov 10Yahoo FinanceARGX
      argenx: Unnatural Products Deal Changes Risk Profile (NASDAQ:ARGX)

      argenx is a Hold with its $550M Unnatural Products deal for an unproven pipeline that may pressure commercial products and R&D. Read more on ARGX stock here.

      Nov 10Seeking AlphaARGX
      If You Invested $100 In argenx Stock 5 Years Ago, You Would Have This Much Today
      Nov 9BenzingaARGX
      Why is argenx stock surging today?
      Nov 9Investing.comARGX
      Argenx to Buy US Biotech for $1.15 Billion to Gain Peptides
      Nov 9BloombergARGX
      Argenx to acquire biotech firm Unnatural Products for $1.15 billion

      Investing.com -- Argenx SE announced Monday it will acquire biotech firm Unnatural Products for $550 million upfront plus contingent value rights tied to development and regulatory milestones, bringing the total potential value to approximately $1.15 billion.

      Nov 9Yahoo FinanceARGX
      argenx to acquire Unnatural Products for up to $1.15 billion
      Nov 9Investing.comARGX
      argenx to Present at Upcoming Investor Conferences
      Nov 3Yahoo FinanceARGX
      arGEN X (0QW0) Gets a Buy from Jefferies

      Tipranks Press Release.

      Oct 29The Globe and MailARGX
      Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX) and Boston Scientific (BSX)

      Detailed price information for Boston Scientific Corp (BSX-N) from The Globe and Mail including charting and trades.

      Oct 27The Globe and MailARGXBSX
      $1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today
      Oct 26BenzingaARGX
      argenx (ENXTBR:ARGX) Stock Looks Overvalued After Its 202% Five Year Run
      Oct 25Yahoo FinanceARGX
      argenx (ENXTBR:ARGX) Posted Q3 2026 Results, Is It Fully Priced?
      Oct 25Yahoo FinanceARGX
      argenx (ENXTBR:ARGX) Reports Positive Phase 3 Data In Autoimmune Myositis
      Oct 24Yahoo FinanceARGX
      Argenx (ENXTBR:ARGX) Stock Faces Margin Questions After Q3 Earnings
      Oct 24Yahoo FinanceARGX
      Argenx's Vyvgart Sales Growth, Pipeline Progress Support Outlook, Oppenheimer Says
      Oct 23Yahoo FinanceARGXOPY
      Argenx's Vyvgart Beats Expectations With Focus Shifting to December Data, RBC Says

      Argenx's (ARGX) Vyvgart sales beat expectations in Q3, with investors focused on upcoming multifocal

      Oct 23Yahoo FinanceARGX
      TD Cowen reiterates argenx stock Buy rating on Vyvgart strength
      Oct 23Investing.comARGX
      Guggenheim lowers argenx stock price target on model update to $1,120
      Oct 23Investing.comARGX
      argenx: 3 Key Takeaways for Long-Term Investors | The Motley Fool

      Pipeline expansion into new indications could sustain growth long after VYVGART matures, a rare diversification for a single-drug biotech.

      Oct 23The Motley FoolARGX
      argenx (ARGX) Q3 2026 Earnings Call Transcript
      Oct 23The Globe and MailARGX
      Baird raises argenx stock price target to $861 on Vyvgart sales
      Oct 22Investing.comARGX
      Jefferies reiterates argenx stock Buy rating after Q3 beat
      Oct 22Investing.comARGX
      Stifel cuts argenx stock price target on mixed quarter results
      Oct 22Investing.comARGX
      argenx Q3 2026 slides: 54% growth fuels 5 potential 2027 launches
      Oct 22Investing.comARGX
      Earnings call transcript: argenx tops revenue forecasts in Q3 2026 on strong growth
      Oct 22Investing.comARGX
      argenx Q3 2026 Earnings Call Transcript
      Oct 22BenzingaARGX
      Argenx Wavers On A Surprise Requirement For Its Flagship Drug

      The company beat sales expectations for its biggest moneymaker.

      Oct 22Investor's Business DailyARGX
      Why is argenx stock sliding today?
      Oct 22Investing.comARGX
      Argenx slips as Q3 operating profit miss offsets Vyvgart sales beat
      Oct 22Yahoo FinanceARGX
      argenx ADR earnings missed by $0.10, revenue topped estimates
      Oct 22Investing.comARGX
      argenx SE (ARGNF) (Q3 2026) Earnings Call Highlights: VYVGART Sales Surge 54% to $1. ...
      Oct 22Yahoo FinanceARGX
      Argenx shares see TD Cowen reiterate Buy on Q3 beat expectations
      Oct 20Investing.comARGX
      RBC Capital Adjusts Price Target on argenx to $1,025 From $1,100, Keeps Outperform Rating
      Oct 20Yahoo FinanceARGX
      RBC Capital cuts argenx stock price target on Sjögren’s setback
      Oct 20Investing.comARGX
      argenx reports positive phase 3 results for myositis treatment
      Oct 19Investing.comARGX
      argenx to Present Phase 3 ALKIVIA Results in Autoimmune Myositis as a Late-Breaking Oral Presentation at ACR Convergence 2026

      Results from the global Phase 3 ALKIVIA study, the first registrational study investigating an FcRn blocker in autoimmune myositis, show efgartigimod provides clinically meaningful improvements in IMNM and DMPatient improvements observed as early as Week 4 and sustained through 52 weeksLate-breaking oral presentation on Wednesday, November 11th, 9:15 – 9:30 AM ET October 19, 2026, 8:00 AM ET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), the immunology innovation company, toda

      Oct 19Yahoo FinanceARGX
      Zacks Investment Ideas feature highlights: Cummins, Argenx and PACCAR

      Cummins, Argenx and PACCAR offer potential buying opportunities after recent pullbacks, backed by strong earnings growth, improving forecasts and long-term business drivers.

      Oct 16Yahoo FinanceARGXPCARCMI
      Is Expanded Argenx Deal Altering The Investment Case For Halozyme Therapeutics (HALO)?
      Oct 16Yahoo FinanceARGX
      Argenx shares may move 5.5% on earnings release next week
      Oct 15Investing.comARGX
      argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026

      October 15, 2026Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that it will host a conference call and audio webcast on Thursday, October 22, 2026 at 2:30 PM CET (8:30 AM ET) to discuss its third quarter 2026 financial results and provide a business update. A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx

      Oct 15Yahoo FinanceARGX
      Analysts Offer Insights on NA Companies: arGEN X (GB:0QW0) and Finnair Oyj (GB:0EG8)

      Tipranks Press Release.

      Oct 11The Globe and MailARGX
      Analysts Are Bullish on Top Healthcare Stocks: Argenx Se (ARGX), Neurocrine (NBIX)

      Detailed price information for Neurocrine Bioscienc (NBIX-Q) from The Globe and Mail including charting and trades.

      Oct 10The Globe and MailARGXNBIX
      argenx (ENXTBR:ARGX) Stock May Be Fully Priced After Its 185% Run
      Oct 10Yahoo FinanceARGX
      Wells Fargo Remains a Buy on Argenx Se (ARGX)

      Detailed price information for Argenx Se ADR (ARGX-Q) from The Globe and Mail including charting and trades.

      Oct 10The Globe and MailARGX
      Argenx Se (ARGX) Receives a Buy from RBC Capital

      Detailed price information for Argenx Se ADR (ARGX-Q) from The Globe and Mail including charting and trades.

      Oct 10The Globe and MailARGX
      argenx Meets Primary Endpoint in Phase II Celiac Disease Study
      Oct 9Yahoo FinanceARGX
      Analysts Are Bullish on These Healthcare Stocks: Argenx Se (ARGX), Edgewise Therapeutics (EWTX)

      Detailed price information for Edgewise Therapeutics Inc (EWTX-Q) from The Globe and Mail including charting and trades.

      Oct 9The Globe and MailARGXEWTX
      argenx: The Sjögren's Selloff Looks Overdone (NASDAQ:ARGX)
      Oct 9Seeking AlphaARGX

      This is the newest page. Registered accounts read further back.